Federal contract award
75N93019C00040
LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541713 — Research and Development in Nanotechnology |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $10.3M |
| Current contract value | $10.3M |
| Potential contract value / ceiling | $10.3M |
| Start date | Sep 16, 2019 |
| Current end date | Sep 15, 2025 |
| Potential end date | Sep 15, 2025 |
| Latest award activity | Sep 1, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 25 of 25 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 1, 2026 | P00024 | $-317 | TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Jan 22, 2025 | P00023 | $-5.0K | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 27, 2024 | P00022 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Jul 11, 2024 | P00021 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Mar 21, 2024 | P00020 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Jan 8, 2024 | P00019 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 18, 2023 | P00018 | $1.9M | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Jul 3, 2023 | P00017 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Mar 28, 2023 | P00016 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Jan 3, 2023 | P00015 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Nov 1, 2022 | P00014 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 26, 2022 | P00013 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 4, 2022 | P00012 | $1.9M | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 3, 2022 | P00011 | $1.1M | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Jun 7, 2022 | P00010 | $0 | IPP: LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Feb 11, 2022 | P00009 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Nov 3, 2021 | P00008 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Oct 14, 2021 | P00007 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Sep 1, 2021 | P00006 | $1.8M | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 2, 2021 | P00005 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Feb 23, 2021 | P00004 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Aug 20, 2020 | P00003 | $1.9M | OPTION 1 - REFINE ANTIBODY SCREENING STRATEGIES |
| Jul 22, 2020 | P00002 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Feb 14, 2020 | P00001 | $0 | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
| Sep 13, 2019 | 0 | $1.7M | LYME DISEASE: B CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.